FGFR2 rearrangements have been detected in 10–15% of intrahepatic cholangiocarcinomas (Arai et al., 2014; Silverman et al., 2019), amplifications in up to 15% of gastric cancers (Deng et al., 2012; Seo et al., 2017) and point mutations in about 10% of endometrial cancers (Byron et al., 2012); moreover, FGFR2 amplification has also a prognostic significance in gastric cancers (Chang et al., 2014; Seo et al., 2017). This evidence concerns the gene FGFR2 and gastric cancer.